KaloBios Initiates Phase 1/2 Trial Of Humaneered(TM) Monoclonal Antibody KB001 For Treatment Of Pseudomonas Infections In Cystic Fibrosis Patients
Apr 3rd 2008Drug InformationCystic Fibrosis
KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced the initiation of a Phase 1/2 clinical trial of KB001, a Humaneered?, high-affinity antibody fragment that KaloBios is developing for the treatment of P. aeruginosa infections. The trial is being conducted in conjunction with the Cystic Fibrosis Foundation and its affiliated organizations.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
